The Latest Cardiac and Vascular News
VANCOUVER, British Columbia, Sept. 24, 2018 (GLOBE NEWSWIRE) — Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, announced today that it has appointed Bernard Fermini, Ph.D.as Chief Research & Development Officer. Dr. Fermini has been […]
VANCOUVER, British Columbia, Aug. 22, 2018 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and twelve months ended June 30, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and are […]
VANCOUVER, British Columbia, June 25, 2018 (GLOBE NEWSWIRE) — Novoheart (“Novoheart” or the “Company”) (TSX-V:NVH) (FWB:3NH) is pleased to announce a presentation was delivered on June 22nd, 2018, entitled “Modeling Cardiac Dysfunction of Friedreich’s Ataxia Using Ventricular Sheets, Tissues and Chambers Engineered […]
VANCOUVER, British Columbia, June 13, 2018 (GLOBE NEWSWIRE) — Novoheart (“Novoheart” or the “Company”) (TSXV:NVH) (FWB:3NH), a global stem cell biotechnology company, announced today that its MyHeart™ platform has been selected as 2018’s “Best New Technology Solution – Drug Development” by MedTech […]
HONG KONG, June 06, 2018 (GLOBE NEWSWIRE) — Novoheart (“Novoheart” or the “Company”) (TSXV:NVH) (FWB:3NH), a global stem cell biotechnology company, is pleased to announce that its wholly owned subsidiary, Novoheart Limited, has been awarded a non-dilutional government grant of C$400,000 from […]
VANCOUVER, British Columbia, May 31, 2018 (GLOBE NEWSWIRE) — Novoheart (“Novoheart” or the “Company”) (TSX-V:NVH) (FWB:3NH), a global stem cell biotechnology company, announced today that it has become a member of the Cardiac Safety Technical Committee of the Health and Environmental Sciences […]
VANCOUVER, BRITISH COLUMBIA — (Marketwired) — Mar 29, 2018 — Novoheart (“Novoheart” or the “Company”) (TSX VENTURE: NVH)(FRANKFURT: 3NH) is pleased to announce that it has filed a patent application on the use of its proprietary MyHeart™ Platform of human bioengineered heart […]
VANCOUVER, BRITISH COLUMBIA — (Marketwired) — Mar 08, 2018 — Novoheart (“Novoheart” or the “Company”) (TSX VENTURE: NVH)(FRANKFURT: 3NH) is pleased to announce that it has published a comprehensive study of the world’s first human heart-in-a-jar, in the prestigious bioengineering journal Biomaterials. The […]
VANCOUVER, BRITISH COLUMBIA — (Marketwired) — Feb 14, 2018 — Novoheart(“Novoheart” or the “Company”) (TSX VENTURE: NVH), through its wholly owned US subsidiary, has entered into a commercial agreement with Sumocor LLC(“Sumocor”), a biotech company based in New York City that is focused […]
VANCOUVER, BRITISH COLUMBIA — (Marketwired) — Jan 16, 2018 — Novoheart(“Novoheart” or the “Company”) (TSX VENTURE: NVH) today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a three-tiered drug screening system […]
